Latigo Biotherapeutics, Inc. (LTGO) Ownership
LTGO ownership summary
as of October 18, 2026- Institutions
- 80.4% of shares outstanding
- Insiders
- 4.98% of shares outstanding
- Shares outstanding
- 66.3M
- Float
- 21.7M shares available to trade
- Short interest
- — 832K shares short
- Days to cover
- 2.26 short interest up 84.9% vs prior month
- Institutions 80.39%
- Insiders 4.98%
- Other investors 14.63%
LTGO top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Fidelity Contrafund | 1.56% | 940K | $13.2M | +940,228 (0.0%) | August 31, 2026 |
| 2 | Fidelity Select Biotechnology | 0.80% | 480K | $6.7M | +480,316 (0.0%) | August 31, 2026 |
| 3 | abrdn Healthcare Investors | 0.42% | 254K | $3.6M | +253,614 (0.0%) | August 31, 2026 |
| 4 | Fidelity Select Health Care | 0.35% | 212K | $3.0M | +212,500 (0.0%) | August 31, 2026 |
| 5 | T. Rowe Price New Horizons | 0.35% | 211K | $3.0M | +211,338 (0.0%) | August 31, 2026 |
| 6 | Fidelity Contrafund K6 | 0.33% | 199K | $2.8M | +199,400 (0.0%) | August 31, 2026 |
| 7 | abrdn Healthcare Opportunities | 0.33% | 196K | $2.7M | +195,783 (0.0%) | August 31, 2026 |
| 8 | Fidelity Advisor Biotechnology I | 0.32% | 191K | $2.7M | +191,400 (0.0%) | August 31, 2026 |
| 9 | abrdn World Healthcare | 0.21% | 126K | $1.8M | +125,603 (0.0%) | August 31, 2026 |
| 10 | abrdn Life Sciences Investors | 0.21% | 125K | $1.8M | +125,000 (0.0%) | August 31, 2026 |
| 11 | Fidelity Advisor Health Care I | 0.17% | 105K | $1.5M | +105,200 (0.0%) | August 31, 2026 |
| 12 | Schwab US Small-Cap ETF™ | 0.16% | 99K | $1.4M | +63 (+0.1%) | September 30, 2026 |
| 13 | Strategic Advisers Fidelity US TtlStk | 0.13% | 78K | $1.1M | +78,500 (0.0%) | August 31, 2026 |
| 14 | Vanguard MStar Total Stk Mkt Idx Invest | 0.09% | 55K | $774,522 | +55,323 (0.0%) | August 31, 2026 |
| 15 | Fidelity VIP Contrafund Initial | 0.09% | 54K | $751,800 | +53,700 (0.0%) | August 31, 2026 |
| 16 | Fidelity Advisor New Insights I | 0.08% | 49K | $688,800 | +49,200 (0.0%) | August 31, 2026 |
| 17 | Fidelity VIP Health Care Initial | 0.06% | 39K | $541,800 | +38,700 (0.0%) | August 31, 2026 |
| 18 | Fidelity Series Opportunistic Insights | 0.05% | 27K | $383,600 | +27,400 (0.0%) | August 31, 2026 |
| 19 | Schwab US Broad Market ETF™ | 0.02% | 12K | $167,902 | — | September 30, 2026 |
| 20 | JHVIT Health Sciences I | 0.01% | 8,327 | $116,578 | +8,327 (0.0%) | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
Who owns LTGO
Institutional investors own 80.4% of Latigo Biotherapeutics's shares and insiders 4.98%.
Related: LTGO analyst forecast, LTGO key metrics. See the LTGO stock overview for the latest quote and news.
LTGO ownership FAQ
What percentage of Latigo Biotherapeutics is owned by institutions?
Institutions hold 80.4% of Latigo Biotherapeutics's shares outstanding; insiders hold 4.98%.
Which funds own Latigo Biotherapeutics?
The largest fund holders of Latigo Biotherapeutics are Fidelity Contrafund (1.56%), Fidelity Select Biotechnology (0.80%), abrdn Healthcare Investors (0.42%), Fidelity Select Health Care (0.35%), T. Rowe Price New Horizons (0.35%).
How many shares of Latigo Biotherapeutics are outstanding?
Latigo Biotherapeutics has 66.3M shares outstanding, of which 21.7M are in the public float.